Research

Metabolic Disease

Elucidating Pathways of Steatohepatitis (EPoS) (UK)

Team:


  • Dr Quentin Anstee

Aim:

To collect longitudinal stool samples in well characterised non-alcoholic fatty liver disease (NAFLD) patients to investigate the impact faecal bacteria diversity has on the development of NAFLD, and importantly the progression to non-alcoholic steatohepatitis (NASH), fibrosis and end stage liver disease.

Research Overview:

The UK is experiencing a dramatic increase in the number of patients presenting with liver disease, which is 5th highest cause of mortality in the UK. This rise in liver disease has been associated with the “obesity epidemic”, pre-disposing to NAFLD. Diet, lack of physical activity and genetics are all key factors that contribute to obesity and NAFLD. There is now a growing body of evidence that the gut microbiota is intrinsically linked with the development and progression of NAFLD.

Research Importance:

This study will aim to develop an understanding of how host and environmental factors interact at cellular, organ and organism level to promote the development of NAFLD and, importantly the progression to fibrosing steatohepatitis (NASH) and end-stage liver disease.